- Home
- KAI vs NAMS Comparison
KAI vs NAMS Comparison
Compare KAI & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KAI | NAMS |
|---|---|---|
| Founded | 1991 | 2019 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.5B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | KAI | NAMS |
|---|---|---|
| Price | $334.62 | $34.93 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $337.50 | $47.38 |
| AVG Volume (30 Days) | 116.7K | ★ 592.3K |
| Earning Date | 02-11-2026 | 02-26-2026 |
| Dividend Yield | ★ 0.41% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 8.65 | N/A |
| Revenue | ★ $1,024,074,000.00 | $35,243,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $10.56 | $11.19 |
| P/E Ratio | $38.56 | ★ N/A |
| Revenue Growth | N/A | ★ 4.91 |
| 52 Week Low | $244.87 | $14.06 |
| 52 Week High | $409.73 | $42.00 |
Technical Indicators
Market Signals| Indicator | KAI | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 61.76 | 57.80 |
| Support Level | $332.95 | $33.14 |
| Resistance Level | $348.22 | $35.62 |
| Average True Range (ATR) | 11.63 | 1.37 |
| MACD | -0.31 | 0.42 |
| Stochastic Oscillator | 75.60 | 92.23 |
Price Performance
Historical ComparisonAbout KAI Kadant Inc
Kadant Inc. supplies process and engineering equipment for papermaking, recycling, lumber manufacturing, and related industries. The company's three reportable segments are the Flow Control segment which consists of the fluid-handling and doctoring, cleaning, & filtration product lines; the Industrial Processing segment which consists of the wood processing and stock-preparation product lines; and Material handling systems, which provides conveyor-belt equipment for industries such as mining, food processing, and packaging. The company has a geographic presence in the U.S., China, Asia, Germany, Canada, and Others.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.